In comparison, asperterpene A showed similar activity to LY2811376, the first orally bioavailable non-peptide BACE1 inhibitor, showing an IC50 range of 239 nM to 249 nM and an EC50 of 300 nM in the context of Alzheimer’s disease at 3xTg-mice. The gene discussed is BACE1; the disease is Alzheimer disease.